Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Paclitaxel

9 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCTHO1415

08/27/2014

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Treatment

VICCPHI1436

08/18/2014

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Treatment

VICCGI13114

08/04/2014

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Treatment

VICCTHO1420

05/19/2014

An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer

Treatment

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment

VICCTHN1257

08/30/2013

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy followed by Standard Chemoradiation/Afatinib in HPV Negative Locally Advanced Stage III/IVa/IVb HNSCC

Treatment

VICCBRE1320

08/16/2013

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Treatment

ECOGTHNE5508

06/29/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Treatment

ECOGTHO4508-M

12/07/2010

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy